574 related articles for article (PubMed ID: 23460534)
1. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
2. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
3. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
5. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Kosaka A; Ohkuri T; Okada H
Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
7. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
8. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
9. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
10. T-cell-independent antitumor effects of CD40 ligation.
Rakhmilevich AL; Alderson KL; Sondel PM
Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
[TBL] [Abstract][Full Text] [Related]
11. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
12. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
13. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
14. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
15. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligation for immunotherapy of solid tumours.
Todryk SM; Tutt AL; Green MH; Smallwood JA; Halanek N; Dalgleish AG; Glennie MJ
J Immunol Methods; 2001 Feb; 248(1-2):139-47. PubMed ID: 11223075
[TBL] [Abstract][Full Text] [Related]
17. The Use of Anti-CD40 mAb in Cancer.
Remer M; White A; Glennie M; Al-Shamkhani A; Johnson P
Curr Top Microbiol Immunol; 2017; 405():165-207. PubMed ID: 25651948
[TBL] [Abstract][Full Text] [Related]
18. The use of agonistic anti-CD40 therapy in treatments for cancer.
Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
[TBL] [Abstract][Full Text] [Related]
19. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.
Jian CZ; Lin L; Hsu CL; Chen YH; Hsu C; Tan CT; Ou DL
Drug Discov Today; 2024 Mar; 29(3):103893. PubMed ID: 38272173
[TBL] [Abstract][Full Text] [Related]
20. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
